Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The KDM7A divergent transcript (KDM7A-DT, also known as JHDM1D-AS1) is a long non-coding RNA transcribed from the antisense strand near the KDM7A gene locus. Unlike the protein-coding KDM7A (a histone demethylase involved in epigenetic regulation), KDM7A-DT acts at the RNA level and may function as a scaffold or guide for chromatin-modifying complexes[4]. Overexpression of KDM7A-DT in fibroblast cells has been shown to induce genotoxic stress, reduce cell proliferation, and alter gene expression profiles associated with stress response and tumorigenesis[7][6]. Its expression correlates with certain cancer subtypes and may serve as a biomarker, particularly in urothelial tumors when analyzed together with JHDM1D/KDM7A expression[5]. However, it is not currently considered a druggable therapeutic target, nor are there drugs known to directly modulate its function.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on JHDM1D antisense RNA 1 (head to head) (JHDM1D-AS1).